Ubrelvy

Drug

About

Thing
Ubrelvy (ubrogepant) is a drug used for the treatment of migraine attacks.
Ubrelvy
Definition
Ubrelvy (ubrogepant) is a drug used for the treatment of migraine attacks.
Ubrelvy
Ubrelvy
Ubrelvy (ubrogepant) is a drug used for the treatment of migraine attacks.

Pronunciation

English

Ubrelvy

Ubrelvy
SpellingUbrelvy
Pronunciation[Ubrelvy]

Mentions

The Food and Drug Administration approved Ubrelvy, the company’s ubrogepant treatment, on Monday. The oral medication is aimed at treating migraines in patients who are unresponsive to common migraine treatments, such as triptans, or are at risk of cardiovascular disorders. Allergan, which anticipated a December approval by the FDA, said Ubrelvy will be available for sale in the U.S. in the first quarter.

The U.S. Food and Drug Administration today approved Ubrelvy (ubrogepant) tablets for the acute (immediate) treatment of migraine with or without aura (a sensory phenomenon or visual disturbance) in adults. Ubrelvy is not indicated for the preventive treatment of migraine. It is the first drug in the class of oral calcitonin gene-related peptide receptor antagonists approved for the acute treatment of migraine.

The drug will be sold under the name Ubrelvy by the pharmaceutical company Allergan. It is considered effective for migraine with or without aura, referring to the sensory or visual disturbances that occur among roughly a third of migraine sufferers.

Ubrelvy, which comes in tablet form, can be effective in treating migraines with aura, a visual disturbance often associated with severe headaches, according to an agency statement.

What was once a debilitating condition may now be easily and quickly treatable thanks to a recent FDA announcement on the approval of a new migraine treatment. The medication, Ubrelvy, was found to work in as little as two hours to offer relief to migraine patients.

New to Cofactor?

Cofactor is a large, structured listing of people, places, and things. Here you can find the description of each topic.

See also

See also: